Publications by authors named "Yi-Qiong Liang"

Article Synopsis
  • The study aimed to develop a CT radiomics model to predict the presence of synchronous distant metastasis (SDM) in patients with clear cell renal cell carcinoma (ccRCC).
  • Researchers analyzed CT images from 172 ccRCC patients, extracting nearly 3000 radiomic features, and used LASSO regression for feature selection, ultimately identifying 9 important features for the prediction model.
  • The model demonstrated effective performance in both training and validation cohorts, indicating its potential as a noninvasive tool for personalized SDM risk assessment in ccRCC patients.
View Article and Find Full Text PDF

This study was purposed to investigate the reversal effect of glucosylceramide synthase (GCS) inhibitor D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) hydrochloride, on multidrug resistance in K562/A02 cells and its mechanism. The IC(50) (the half maximal inhibitory concentration) of PDMP was measured by MTT method. Cell apoptosis and intracellular daunorubicin (DNR) concentration were detected by flow cytometry.

View Article and Find Full Text PDF

This study was aimed to explore the potential therapy of Gambogic acid (GA) combined with magnetic nanoparticle of Fe3O4 (Fe3O4-MNP) on leukemia. The proliferation of U937 cells and the cytotoxicity were evaluated by MTT assay. Cell apoptosis was observed and analyzed by microscopy and flow cytometry respectively.

View Article and Find Full Text PDF

Recent work indicates that an Aurora kinase inhibitor MK-0457 (VX-680), a small-molecule inhibitor of Aurora kinases A, B, C and BCR-ABL, FLT-3, JAK-2, can block the progression of cell growth cycle, causing apoptosis in a range of human tumors. MK-0457 has the activity against expressions of wild-type and mutated bcr-abl gene, including the T315I mutant, and can inhibit the activity of FLT-3, JAK-2 and their mutated types as well. Clinical applications suggest that the MK-0457 has therapeutic effect on the highly refractory CML and CML with poor prognosis, Ph(+) ALL with T315I mutant, relapse refractory AML and JAK-2 positive myeloproliferative diseases (MPD).

View Article and Find Full Text PDF